trending Market Intelligence /marketintelligence/en/news-insights/trending/CGS_AwumOAjPkVptauXbdw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In This List

Hisamitsu Pharmaceutical's schizophrenia skin patch gets US FDA approval

S&P Global Market Intelligence

Cannabis Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Hisamitsu Pharmaceutical's schizophrenia skin patch gets US FDA approval

A unit of Hisamitsu Pharmaceutical Co. Inc. said the U.S. Food and Drug Administration has approved Secuado, an over-the-skin patch for treating adults with schizophrenia.

The Japanese drugmaker Hisamitsu and its U.S. unit Noven Pharmaceuticals Inc. submitted an application to the FDA in December 2018 seeking approval of Secuado to treat symptoms of schizophrenia. Secuado is a transdermal drug delivery system worn for a period of 24 hours to deliver the antipsychotic drug asenapine. The therapy provides doctors a new delivery option and a nonintrusive, visual confirmation that a patient is taking their medication, according to Noven's Oct. 15 press release.

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels and behaves.

Secuado carries a boxed warning that the patch should not be used for treating people with dementia-related psychosis. Noven said medicines like Secuado can raise the risk of death in elderly people who have lost touch with reality due to confusion and memory loss.

The company said the medicine's approval was backed with data from a phase 3 trial that showed the drug improved the symptoms of schizophrenia.